GLP-1 Market
LLY $1164.89 ▲ +1.0% NVO $39.80 ▼ -8.0% PFE $27.74 ▲ +0.3% VKTX $30.11 ▲ +3.9% KLRA $11.99 ▼ -6.5% GPCR $36.81 ▲ +5.2% RHHBY $55.30 ▲ +2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

GNR-055 1.0-2.0- /kg

GNR-055 1.0-2.0- /kg

Company
AO GENERIUM
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 22, 2026

Trial details
  • Completed NCT NCT04539340

    A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

    Not yet reported AO GENERIUM 20 participants Est. completion 2020-09-08 1 site
    Other conditions: Mucopolysaccharidosis Type II, Metabolic Diseases
    View official trial listing →
  • Active, not recruiting NCT NCT05208281

    A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

    Not yet reported, Not yet reported AO GENERIUM 32 participants Est. completion 2028-03 5 sites Stand-alone
    Other conditions: Mucopolysaccharidosis Type II, Metabolic Diseases
    View official trial listing →
  • Completed NCT NCT06475404

    A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

    Not yet reported AO GENERIUM 18 participants Est. completion 2023-09-20 1 site
    Other conditions: Mucopolysaccharidosis Type II, Metabolic Diseases
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: GNR-055 1.0-2.0- /kg, GNR-055 1.0-2.0-3.0 mg/kg, GNR-055, GNR-055 2.0 mg/kg, GNR-055 3.0 mg/kg

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.